J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

0:00-19:48

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.

Publisher

BioSpace

Published

October 14, 2026

Duration

20 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#jsdisappointingq3 #revmedssubgroupdata #bmsmixedresults #lifesciences

The Nile